Some investigations of tumor specimens resistant to CDK4/6 inhibitors revealed various possible resistance pathways, including upstream changes in AKT1, KRAS, HRAS, NRAS, FGFR2, and ERBB2 [66]. The gene discussed is CDK4; the disease is neoplasm.